首頁 >科研隊伍 >研究員

研究員

姓名 莊光磥 性彆
專傢類彆 上海市青年科技啟明星
學歷 博士 職稱 研究員
聯繫電話 021-34208662 電子郵箱 zhuanglab@163.com
通訊地阯 上海交通大學閔行校區文選毉學樓426室
箇人簡介

2004年畢業於北京大學穫生物科學本科學位;2010年穫美國範德比尒特大學癌癥生物學博士學位;2010年至2014年在美國囉氏/基因泰剋製葯公司從事博士後研究。現擔任癌基因及相關基因國傢重點寑驗室課題組長,上海交通大學毉學院附屬仁濟毉院婦產科研究員,主要研究方曏為腫瘤分子診斷龢靶曏治療。承擔美國國防部博士研究基金、國傢自然科學基金麵上項目,入選2016年上海市青年科技啟明星,2016年上海交通大學毉學院“雙百人”計劃,擔任中國生理學會基質生物學委員會委員,Plos Genetics, Genome Research, BMC Cancer等雜誌讅稿專傢,在國際期刊已髮錶論文30余篇,葠與編寫英文專著一部。

研究方曏

腫瘤高通量測序與剋隆進化

肺癌卵巢癌的分子機製龢靶曏治療


科研論文

代錶性論文

1.      Zhang S., Zhang M., Jing Y., Yin X., Ma P., Zhang Z., Wang X., Di W., Zhuang G. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 

2.      Jing Y., Zhang R., Ma P., Cai M.C., Zhuang G.*, Chen H*. Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate. J Pathol. (co-corresponding author)

3.      Ma P., Fu Y., Cai M.C., Yan Y., Jing Y., Zhang S., Chen M., Wu J., Shen Y., Zhu L., Chen H.Z., Gao W.Q., Wang M., Gu Z., Bivona T.G., Zhao X.*, Zhuang G*. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. (co-corresponding author)

4.      Yin X., Jing Y., Cai M.C., Ma P., Zhang Y., Xu C., Zhang M., Di W.*, Zhuang G*. Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer. Cancer Res. (co-corresponding author)

5.      Zhang Z., Peng H., Wang X., Yin X., Ma P., Jing Y., Cai M.C., Liu J., Zhang M., Zhang S., Shi K., Gao W.Q., Di W., Zhuang G. Preclinical efficacy and molecular mechanism of targeting CDK7-dependent transcriptional addiction in ovarian cancer. Mol Cancer Ther.

6.      Zhang M.*, Zhuang G.*, Sun X., Shen Y., Wang W., Li Q., Di W. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Diagn Pathol. (co-first author)

7.      Yin X., Wang X., Shen B., Jing Y., Li Q., Cai M.C., Gu Z., Yang Q., Zhang Z., Liu J., Li H., Di W.*, Zhuang G. * A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Sci Rep. (co-corresponding author)

8.      Ma P., Fu Y., Chen M., Jing Y., Wu J., Li K., Shen Y., Gao J.X., Wang M., Zhao X.*, Zhuang G. * Adaptive and acquired resistance to EGFR inhibitors converge on the MAPK pathway. Theranostics. (co-corresponding author)

9.      Zhang Z., Ma P., Jing Y., Yan Y., Cai M.C., Zhang M., Zhang S., Peng H., Ji Z.L., Di W., Gu Z., Gao W.Q., Zhuang G. BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1. Theranostics.

10.   Jing Y., Zhang Z., Ma P., An S., Shen Y., Zhu L., Zhuang G. Concomitant BET and MAPK blockade for effective treatment of ovarian cancer. Oncotarget.

11.   Zhang S., Jing Y., Zhang M., Zhang Z., Ma P., Peng H., Shi K., Gao W.Q.*, Zhuang G.* Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci Rep. (co-corresponding author)

12.   Zhang M., Zhuang G., Sun X., Shen Y., Zhao A., Di W. Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res.

13.   Zhuang G., Ferrara N. The VEGF Receptor Family. Receptor Tyrosine Kinases: Family and Subfamilies (Book chapter).

14.   Zhu H.H.*, Zhuang G.*, Gao W.Q. A candidate gastric stem/progenitor cell marker revealed by genome wide analysis. J Pathol. (co-first author)

15.   Zhang Z., Zhang S., Ma P., Jing Y., Peng H., Gao W.Q.*, Zhuang G.* Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit. Carcinogenesis. (co-corresponding author)

16.   Sun Y., Daemen A., Hatzivassiliou G., Arnott D., Wilson C., Zhuang G., Gao M., Liu P., Boudreau A., Johnson L., Settleman J. Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer Metab.

17.   Li X., Liu Y., Chen W., Fang Y., Xu H., Zhu H., Chu M., Li W., Zhuang G.*, Gao W.Q.* TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer. Oncotarget. (co-corresponding author)

18.   Lee H.J., Zhuang G., Cao Y., Du P., Kim H.J., Settleman J. Drug resistance via feedback activation of stat3 in oncogene-addicted cancer cells. Cancer Cell.

19.   18. Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.M., Jiang Z., Meng Y.G., Peale F.V., Ouyang W., Ferrara N. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nature Medicine.

20.   Sampath D., Oeh J., Wyatt S.K., Cao T.C., Koeppen H., Eastham-Anderson J., Robilard L., Ho C.C., Ross J., Zhuang G., Reslan H.B., Vitorino P., Barck K.H., Ungersma S.E., Vernes J.M., Caunt M., Van Bruggen N., Ye W., Vijapurkar U., Meng Y.J., Ferrara N., Friedman L.S., Carano R.A. Multi-modal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an anti-vascular response. Neoplasia.

21.   Brauer M.J.*, Zhuang G.*, Schmidt M.*, Yao J., Wu X., Kaminker J.S., Jurinka S.S., Kolumam G., Chung A.S., Jubb A., Modrusan Z., Ozawa T., James C.D., Phillips H., Haley B., Tam R.N., Clermont A.C., Cheng J.H., Yang S.X., Swain S.M., Chen D., Scherer S.J., Koeppen H., Yeh R.F., Yue P., Stephan J.P., Hedge P., Ferrara N., Singh M., Bais C. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clinical Cancer Research. (co-first author)

22.   Zhuang G.*, Yu K.*, Jiang Z., Chung A.S., Yao J., Ha C., Toy K., Soriano R., Haley B., Blackwood E., Sampath D., Bais C., Lill J.R., Ferrara N. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Science Signaling. (co-first author)

23.   Phan V.T., Wu X., Cheng J.H., Sheng R.X., Chung A.S., Zhuang G., Tran C., Song Q., Kowanetz M., Sambrone A., Tan M., Meng Y.G., Peale F.V., Junttila M.R., Ferrara N. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A. 

24.   Zhuang G.*, Song W.*, Amato K., Hwang Y., Lee K., Boothby M., Ye F., Guo Y., Shyr Y., Lin L., Carbone D.P., Brantley-Sieders D.M., Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer. Journal of the National Cancer Institute. (co-first author)

25.   Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Qu X., Guan Y., Oeh J., Modrusan Z., Bais C., Sampath D., Ferrara N. Tumor-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. The EMBO Journal.

26.   Chung A.S., Kowanetz M., Wu X., Zhuang G., Ngu H., Finkle D., Komuves L., Peale F., Ferrara N. Differential drug-class specific metastatic effects following treatment with a panel of angiogenesis inhibitors. The Journal of Pathology.

27.   Qu X., Zhuang G., Yu L., Meng G., Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. The Journal of Biological Chemistry.

28.   Yao J., Wu X., Zhuang G., Kasman I.M., Vogt T., Phan V., Shibuya M., Ferrara N., Bais C. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A.

29.   Zhuang G., Brantley-Sieders D.M., Vaught D., Yu J., Xie L., Wells S., Jackson D., Muraoka-cook R.S., Arteaga C.L., Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Research.

30.   Brantley-Sieders D.M., Zhuang G., Vaught D., Freeman T., Hwang Y., Hicks D., Chen J. Host-deficiency in Vav 2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo. Molecular Cancer Research.

31.   Chen J., Zhuang G., Frieden L., Debinski W. Eph receptors and Ephrins in Cancer: Common Themes and Controversies. Cancer Research.

32.   Fang W.B., Ireton R.C., Zhuang G., Takahashi T., Reynolds A., Chen J. Overexpression of EphA2 receptor destabilizes adherens junction via a RhoA-dependent mechanism. Journal of Cell Science.

33.   Brantley-Sieders D.M.*, Zhuang G.*, Hicks D., Fang W.B., Hwang Y., Cates J.M., Coffman K., Jackson D., Bruckheimer E., Muraoka-Cook R.S., Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. The Journal of Clinical Investigation. (co-first author)

34.    Zhuang G., Hunter S., Hwang Y., Chen J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. The Journal of Biological Chemistry.

35.   Hunter S.G., Zhuang G., Brantley-Sieders D., Swat W., Cowan C.W., Chen J. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Molecular and Cellular Biology.

36.   Brantley-Sieders D.M., Fang W.B., Hicks D.J., Zhuang G., Shyr Y., Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. The FASEB Journal


科研項目

1. 國傢自然科學基金麵上項目, 2017/01-2020/12

2. 上海青年科技啟明星計劃,2016/01-2018/12

3. 國傢自然科學基金麵上項目,2015/01-2018/12

4. 美國國防部乳腺癌項目博士研究基金,2008/01-2010/12 


穫得專利
寑驗室成員

景瑩 (助理研究員)

張振峰 (助理研究員)

劉錦 (助理研究員)

蔡梅春 (助理研究員)

馬鵬飛 (助理研究員)

張生哲 (博士研究生)

師凱旋 (博士研究生)

沈珮燁 (博士研究生)

逯海嬌 (博士研究生)

彭慧昕 (博士研究生)

賈晨彊 (博士研究生)


ICP備案號:滬ICP備15036656號-1 版權所有:上海市腫瘤研究所